Loading...

Nexalin Technology, Inc.

NXLIWNASDAQ
Healthcare
Medical - Devices
$0.05
$-0.02(-33.57%)

Nexalin Technology, Inc. NXLIW Peers

See (NXLIW) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Devices Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NXLIW$0.05-33.57%16.3MN/AN/AN/A
ABT$136.01+1.21%236.6B17.68$7.69+1.68%
BSX-PA$122.18+2.37%175.4B230.53$0.53N/A
BSX$107.41+0.83%158.8B78.37$1.37N/A
SYK$395.63+0.53%151.2B53.54$7.39+0.84%
MDT$87.17+1.34%111.7B24.15$3.61+3.22%
EW$78.21+0.00%45.9B32.31$2.42N/A
DXCM$87.29+1.11%34.2B65.63$1.33N/A
STE$240.22+0.60%23.6B38.99$6.16+0.95%
PHG$23.98-0.66%22.2B79.93$0.30+3.70%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NXLIW vs ABT Comparison

NXLIW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NXLIW stands at 16.3M. In comparison, ABT has a market cap of 236.6B. Regarding current trading prices, NXLIW is priced at $0.05, while ABT trades at $136.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NXLIW currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 17.68. In terms of profitability, NXLIW's ROE is -2.78%, compared to ABT's ROE of +0.31%. Regarding short-term risk, NXLIW is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for NXLIW.

Stock Price Comparison

Loading...

Frequently Asked Questions

;